Drug intelligence / Profile preview

Imunoglukan P4H ACUTE

Development stage
Unknown
Lead developer
Pleuran
Modality
Small Molecules
Administration
Oral
01

Overview

Imunoglukan P4H ACUTE is an approved, marketed food supplement developed and manufactured by Pleuran for intensive, short-term immune and respiratory tract support, particularly during the first signs of exhaustion, fatigue, or respiratory infections. It is formulated as a combination of Imunoglukan (IMG), a highly purified insoluble beta-1,3/1,6-D-glucan (pleuran) extracted from the oyster mushroom (*Pleurotus ostreatus*), alongside vitamin C (L-ascorbic acid) and zinc. The liquid formulation also incorporates five plant extracts: *Drosera rotundifolia*, *Sambucus nigra*, *Sisymbrium officinale*, *Ribes nigrum*, and *Pelargonium sidoides*. Imunoglukan acts as an immunomodulator by binding to pattern recognition receptors, primarily C-type lectin domain family 7 member A (Dectin-1), on innate immune cells (such as macrophages and dendritic cells) to stimulate innate and adaptive immune responses. Vitamin C and zinc serve as essential micronutrients that synergistically support cellular immune functions and protect cells from oxidative stress.

Brand names
Imunoglukan P4H ACUTEImunoglukan P4H ACUTE!
Other names
pleuran + ascorbic acid + zinc
02

Targets

CARD9 (Caspase recruitment domain-containing protein 9)αMβ2 (Integrin αMβ2)LacCer (Lactosylceramide)SYK (Spleen Tyrosine Kinase)CD36 (CD36 antigen)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)TLR6CLEC7A (Dectin-1)

Beyond the preview

Go deeper on Imunoglukan P4H ACUTE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Imunoglukan P4H ACUTE.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call